The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer
Daniel H Ahn, Tanios Bekaii-Saab
JAMA Oncol . 2022 Jul 14. doi: 10.1001/jamaoncol.2022.2309. Online ahead of print.
Pancreatic ductal adenocarcinoma (PDAC) remains the third leading cause of cancer-associated deaths in the US and is on pace to become the second leading cause of cancer-related mortality.1 Improvements in outcomes for those affected by pancreas cancer are primarily because of more effective systemic therapies. This includes the approval of olaparib maintenance therapy for patients with germline BRCA-variated metastatic pancreatic cancer2 and FOLFIRINOX or gemcitabine/capecitabine adjuvant chemotherapy regimens based off the PRODIGE24-ACCORD and ESPAC-4 trials, which demonstrated an improvement in overall survival.3,4
Read Full Article Here: https://doi.org/10.1001/jamaoncol.2022.2309